Your Messages Inbox (1) 
Your Unread Messages
See All
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial
The Lancet Oncology - Online First, 11/11/09
Joensuu H et al. – The capecitabine-containing chemotherapy regimen reduced breast cancer recurrence compared with a control schedule of standard agents. Capecitabine administration was frequently discontinued because of adverse effects.
Methods- Open-label trial
- Randomly assigned (centrally by computer; stratified by node status, HER2 status, and centre) 1500 women with axillary node-positive or high-risk node-negative breast cancer to either 3 cycles of capecitabine and docetaxel followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (capecitabine group, n=753), or to three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (control group, n=747)
- Primary endpoint recurrence-free survival
- Planned interim analysis done after 3 years' median follow-up
- Efficacy analyses by modified intention to treat
- 2 patients in each group excluded from efficacy analyses because of withdrawal of consent or distant metastases
- After median follow-up of 35 months (IQR 25·5—43·6), recurrence-free survival at 3 years was better with capecitabine regimen than with control (93% vs 89%; hazard ratio 0·66, 95% CI 0·47—0·94)
- Capecitabine regimen associated with more cases of grade 3 or 4 diarrhoea (46/740 [6%] vs 25/741 [3%]) and hand-foot syndrome (83/741 [11%] vs 2/741 [<1%]) and control regimen with more occurrences of grade 3 or 4 neutropenia (368/375 [98%] vs 325/378 [86%]) and febrile neutropenia (65/741 [9%] vs 33/742 [4%])
- More patients discontinued planned treatment in capecitabine group than in control group (178/744 [24%] vs 23/741 [3%])
- 4 patients in capecitabine group and 2 in control group died from potentially treatment-related causes
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): A phase II randomised trial
The Lancet Oncology - Online First, 02/09/10
Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials
The Lancet Oncology - Online First, 02/09/10
Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation
BMC Cancer, 02/09/10
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): A phase II randomised trial
The Lancet Oncology - Online First, 02/09/10
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
Cancer Chemotherapy and Pharmacology, 02/09/10
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer
Cancer Chemotherapy and Pharmacology, 02/09/10
Article Search
Sponsor
Sponsor